» Articles » PMID: 37554732

The HEARTS Partner Forum-supporting Implementation of HEARTS to Treat and Control Hypertension

Abstract

Cardiovascular diseases (CVD), principally ischemic heart disease (IHD) and stroke, are the leading causes of death (18. 6 million deaths annually) and disability (393 million disability-adjusted life-years lost annually), worldwide. High blood pressure is the most important preventable risk factor for CVD and deaths, worldwide (10.8 million deaths annually). In 2016, the World Health Organization (WHO) and the United States Centers for Disease Control (CDC) launched the Global Hearts initiative to support governments in their quest to prevent and control CVD. HEARTS is the core technical package of the initiative and takes a public health approach to treating hypertension and other CVD risk factors at the primary health care level. The HEARTS Partner Forum, led by WHO, brings together the following 11 partner organizations: American Heart Association (AHA), Center for Chronic Disease Control (CCDC), International Society of Hypertension (ISH), International Society of Nephrology (ISN), Pan American Health Organization (PAHO), Resolve to Save Lives (RTSL), US CDC, World Hypertension League (WHL), World Heart Federation (WHF) and World Stroke Organization (WSO). The partners support countries in their implementation of the HEARTS technical package in various ways, including providing technical expertise, catalytic funding, capacity building and evidence generation and dissemination. HEARTS has demonstrated the feasibility and acceptability of a public health approach, with more than seven million people already on treatment for hypertension using a simple, algorithmic HEARTS approach. Additionally, HEARTS has demonstrated the feasibility of using hypertension as a pathfinder to universal health coverage and should be a key intervention of all basic benefit packages. The partner forum continues to find ways to expand support and reinvigorate enthusiasm and attention on preventing CVD. Proposed future HEARTS Partner Forum activities are related to more concrete information sharing between partners and among countries, expanded areas of partner synergy, support for implementation, capacity building, and advocacy with country ministries of health, professional societies, academy and civil societies organizations. Advancing toward the shared goals of the HEARTS partners will require a more formal, structured approach to the forum and include goals, targets and published reports. In this way, the HEARTS Partner Forum will mirror successful global partnerships on communicable diseases and assist countries in reducing CVD mortality and achieving global sustainable development goals (SDGs).

Citing Articles

Population-based approaches to increase hypertension control: an urgent need.

Richardson C, Battle S, DiPette D Hypertens Res. 2024; 48(3):1195-1197.

PMID: 39592823 DOI: 10.1038/s41440-024-02022-w.


A Cross-Sectional Survey of Fixed-Dose Combination Antihypertensive Medicine Prescribing in Twenty-Four Countries, Including Qualitative Insights.

OHagan E, McIntyre D, Nguyen T, Tan K, Hanlon P, Siddiqui M Glob Heart. 2024; 19(1):73.

PMID: 39281000 PMC: 11396169. DOI: 10.5334/gh.1353.


Optimal Antihypertensive Systolic Blood Pressure: A Systematic Review and Meta-Analysis.

Whelton P, OConnell S, Mills K, He J Hypertension. 2024; 81(11):2329-2339.

PMID: 39263736 PMC: 11483200. DOI: 10.1161/HYPERTENSIONAHA.124.23597.


Blood pressure and the hypertension care cascade in The Gambia: Findings from a nationwide survey.

Jobe M, Mactaggart I, Hydara A, Kim M, Bell S, Kotanmi G J Clin Hypertens (Greenwich). 2024; 26(5):563-572.

PMID: 38563710 PMC: 11088434. DOI: 10.1111/jch.14806.


[HEARTS in the Americas: targeting health system change to improve population hypertension controlHEARTS nas Américas: impulsionar mudanças no sistema de saúde para melhorar o controle da hipertensão arterial na população].

Ordunez P, Campbell N, DiPette D, Jaffe M, Rosende A, Martinez R Rev Panam Salud Publica. 2024; 48:e17.

PMID: 38464870 PMC: 10924616. DOI: 10.26633/RPSP.2024.17.


References
1.
. Worldwide trends in hypertension prevalence and progress in treatment and control from 1990 to 2019: a pooled analysis of 1201 population-representative studies with 104 million participants. Lancet. 2021; 398(10304):957-980. PMC: 8446938. DOI: 10.1016/S0140-6736(21)01330-1. View

2.
Ordunez P, Campbell N, Giraldo Arcila G, Angell S, Lombardi C, Brettler J . HEARTS in the Americas: innovations for improving hypertension and cardiovascular disease risk management in primary care. Rev Panam Salud Publica. 2022; 46:e96. PMC: 9288223. DOI: 10.26633/RPSP.2022.96. View

3.
Salam A, Huffman M, Kanukula R, Hari Prasad E, Sharma A, Heller D . Two-drug fixed-dose combinations of blood pressure-lowering drugs as WHO essential medicines: An overview of efficacy, safety, and cost. J Clin Hypertens (Greenwich). 2020; 22(10):1769-1779. PMC: 8030031. DOI: 10.1111/jch.14009. View

4.
Al-Makki A, DiPette D, Whelton P, Murad M, Mustafa R, Acharya S . Hypertension Pharmacological Treatment in Adults: A World Health Organization Guideline Executive Summary. Hypertension. 2021; 79(1):293-301. PMC: 8654104. DOI: 10.1161/HYPERTENSIONAHA.121.18192. View

5.
Valdes Gonzalez Y, Campbell N, Pons Barrera E, Calderon Martinez M, Perez Carrera A, Morales Rigau J . Implementation of a community-based hypertension control program in Matanzas, Cuba. J Clin Hypertens (Greenwich). 2020; 22(2):142-149. PMC: 8029874. DOI: 10.1111/jch.13814. View